Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report

• Published in: Journal of medical case reports Vol. 17; no. 1; pp. 177 - 6
• Main Authors: Ciuoderis, Karl, Perez, Laura, Alvarez, Catalina, Usuga, Jaime, Carvajal, Leidi, Cardona, Andrés, Maya, Maria A., Cloherty, Gavin, Hernandez-Ortiz, Juan P., Osorio, Jorge E.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 04.05.2023; BioMed Central; BMC
• Subjects: Adult; Amino acids; Analysis; Antibodies, Viral; Biological response modifiers; Case Report; Case reports; Chemokines; Coronaviruses; COVID-19; COVID-19 vaccines; Cytokines; Development and progression; Disease; DNA sequencing; Genomes; Genomics; Health aspects; Hispanic Americans; Humans; Immunoglobulins; Infections; Interferon; Interferon gamma; Interleukins; Male; Medical research; Medicine, Experimental; Mutation; Nucleotide sequencing; Pathogenesis; Pharmaceutical industry; Postvaccination; Proteins; Rash; SARS-CoV-2; Serology; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Skin; Steroids; Tumor necrosis factor-TNF; Urticaria; Urticaria - etiology; Vaccination; Viral infections; Whole genome sequencing; Colombia; United States; United States > US; Case report; Rash; SARS-CoV-2; Skin; Postvaccination; Urticaria
• ISSN: 1752-1947; 1752-1947
• DOI: 10.1186/s13256-023-03904-2

Severe acute respiratory syndrome coronavirus 2 continues to threaten public health. The virus is causing breakthrough infections in vaccinated individuals. Also, scarce information is available about cutaneous manifestations after severe acute respiratory syndrome coronavirus 2 infection. A case of a triple-vaccinated (Pfizer) 37-year-old Hispanic American (Colombian) male who developed urticaria after Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 breakthrough infection is described. Virus isolation and whole genome sequencing along with immune and molecular assays were performed. Dermatological manifestations (skin rash and urticaria) after Omicron BA.5.1 infection were observed. Sequence analysis of the Omicron BA.5.1 isolate also revealed several important mutations. Hemogram analysis revealed leukocytosis and neutrophilia. Serology testing revealed anti-spike immunoglobulin G serum titers but negative detection of immunoglobulin M at 10 days after symptom onset. Anti-nucleocapsid, anti-spike 1 immunoglobulin G, anti-spike trimer, and anti-receptor-binding-domain immunoglobulin G and immunoglobulin E sera were detected at different titers 10 days after symptom onset. Several serum levels of chemokines/cytokines (Interferon-α, interferon-γ, interleukin-12/interleukin-23p40, interleukin-18, interferon gamma-induced protein-10, monocyte chemoattractant protein-1, monokine induced by gamma, macrophage inflammatory protein-1α, chemokine (C-C motif) ligand-5 , tumor necrosis factor-β1, Tumor necrosis factor-α) were detected, but interleukin-2, interleukin-4, interleukin-6, interleukin-8, and interleukin-17A were below the limit of detection. To our knowledge, this is the first study describing skin effects of a severe acute respiratory syndrome coronavirus 2 Omicron BA.5 variant breakthrough infection in a triple-vaccinated patient in Colombia. Several important mutations were found in the spike glycoprotein of the virus isolated; these mutations are associated with immune evasion and changes in antigenic properties of the virus. Physicians overseeing coronavirus disease 2019 cases should be aware of the potential skin effects of the infection. Pathogenesis of severe acute respiratory syndrome coronavirus 2 infection and its association with proinflammatory cytokines and chemokines may enhance the development of urticaria and other skin manifestations in immunized individuals. However, further studies are needed to better understand the complexity of coronavirus disease in such situations.